Diabetes drugmaker Novo Nordisk (NYSE:NVO) posted Street-beating second quarter results today, lifting its full-year sales forecast despite lingering concerns relating to U.S. drug pricing pressures. Last year, the Danish company saw shares drop more than 40% after it slashed its long-term operating profit forecasts, citing price pressures in the U.S. market. Today, Novo Nordisk raised its […]
Diabetes
Sanofi brings another insulin glargine patent suit against Merck
Sanofi Aventis (NYSE:SNY) yesterday filed another patent lawsuit against Merck Sharp & Dohme Corp. (NYSE:MRK), alleging that Merck’s product infringes upon two patents covering Sanofi’s insulin glargine product, Lantus. In July, Merck won tentative approval for its follow-on biologic version of Sanofi’s Lantus. The agency’s final regulatory nod is contingent upon the resolution of these patent infringement […]
MannKind posts mixed Q2
Shares in MannKind Corp. (NSDQ:MNKD) fell slightly this morning after the biopharmaceutical company missed earnings expectations but beat sales estimates on Wall Street with its second quarter results. The Valencia, Calif.-based company posted a net loss of -$35.4 million on sales of $2.2 million for the 3 months ended June 30, for bottom-line loss of -18% on […]
MannKind combines inhaled insulin with One Drop’s digital diabetes tech
MannKind Corp. (NSDQ:MNKD) and One Drop said today that the group launched its A-One trial evaluating MannKind’s inhaled insulin, Afrezza, for use with One Drop’s digital diabetes management platform. The companies reported that they are enrolling people with Type II diabetes and randomizing them in two treatment arms. One group of patients will use Afrezza with […]
ViaCyte launches cell replacement trial for Type I diabetes
Regenerative medicine company ViaCyte said today that the first patients have been implanted in a trial of its islet cell replacement therapy, PEC-Direct. San Diego-based ViaCyte is developing the cell therapy as a functional cure for patients with Type I diabetes who are at risk of suffering acute life-threatening complications. The company’s open-label clinical trial […]
Tandem shares slide after Q2 sales miss
Shares in Tandem Diabetes Care (NSDQ:TNDM) fell yesterday after the medical device maker missed sales expectations but beat EPS estimates on Wall Street with its second quarter results. The San Diego, Calif.-based company posted a loss of -$21.8 million, or -44¢ per share, on sales of $21.3 million for the 3 months ended June 30, for […]
Roche taps Accenture’s analytics tech for digital diabetes management
Accenture (NYSE:ACN) said today that it inked a five-year deal with Roche (OTC:RHHBY) to incorporate its analytics platform into Roche’s digital diabetes management system. According to the deal, Roche’s new digital “diabetes ecosystem” will be built on the Accenture Intelligent Patient Platform. The system reportedly allows Roche to collect and analyze data from diabetes patients in […]
Lilly tops Q2 earnings, revenue estimates
Shares in Eli Lilly (NYSE:LLY) fell today even though the drugmaker beat expectations on Wall Street with its second quarter results. The Indianapolis-based company posted profits of $1.01 billion, or 95¢ per share, on sales of $5.82 billion for the 3 months ended June 30, for bottom-line growth of 35% on sales growth of 8% compared […]
AntriaBio launches trial of once-weekly insulin
AntriaBio (OTC:ANTB) said today that the first patient was dosed in a Phase I first-in-human trial of its once-weekly basal insulin. The single ascending dose study is designed to test the safety, pharmacokinetics and dynamics of AB101 in patients with Type I diabetes. The second part of the study is slated to compare AB101 to Sanofi‘s […]
Senseonics inks artificial pancreas deal with Roche, TypeZero Technologies
Senseonics (NYSE:SENS) said today that it inked a collaboration with TypeZero Technologies and Roche (OTC:RHHBY) Diabetes Care to develop an automated insulin delivery system. The deal is part of an NIH-funded effort to test artificial pancreas systems. The trial is slated to integrate Senseonic’s Eversense glucose monitor, TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight insulin pump. […]